New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: StemCells Inc (NASDAQ:STEM), Gold Fields Limited (ADR) (NYSE:GFI), CBIZ, Inc (NYSE:CBZ), Progenics Pharmaceuticals, Inc (NASDAQ:PGNX)
StemCells Inc (NASDAQ:STEM) showed a volume of 2.29 million shares by the end of last trade whereas the average volume of the stock remained 586,094.00 shares. The stock opened the session at $1.35 but then moved to $1.44. At that price, the stock showed a positive performance of 4.35%. StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company’s primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents.
Will STEM Continue To Move Higher? Find Out Here
Gold Fields Limited (ADR) (NYSE:GFI) opened the session at $3.18 and closed the session at $3.20. The stock showed a negative performance of 0.63% in previous trading session. Gold Fields Limited (Gold Fields) is a holding company. Gold Fields is engaged in gold mining and related activities, including exploration, extraction, processing and smelting. Gold Fields is a producer of gold and holder of gold reserves in South Africa, Ghana, Australia and Peru. In Peru, Gold Fields also produces copper. Gold Fields is primarily involved in underground and surface gold and copper mining and related activities. Gold Fields also has an interest in a platinum group metal exploration project in Finland. Gold bullion is its principal product, which is produced in South Africa,
For How Long GFI will fight for Profitability? Read This Trend Analysis report
CBIZ, Inc (NYSE:CBZ) opened the session at $8.95 and closed the session at $9.03. The stock showed a positive performance of 1.01% in previous trading session. Traded with volume of 2.26 million shares in the prior session and the average volume of the stock remained 294,296.00 shares. The beta of the stock remained 0.69. CBIZ, Inc. (CBIZ) provides professional business services, products and solutions. These services are provided to businesses of various sizes, as well as individuals, governmental entities and not-for-profit enterprises throughout the United States and parts of Canada. CBIZ delivers its services through four practice groups: Financial Services, Employee Services, and National Practices. Its Financial Services group includes accounting, tax, financial advisory, valuation, litigation support, internal audit,
Why Should Investors Buy CBZ After The Recent Gain? Just Go Here and Find Out
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) the stock advanced 7.68% and finished the session at $5.89. Traded with volume of 2.23 million shares in the prior session and the average volume of the stock remained 905,095.00 shares. The beta of the stock remained 1.24. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC,
Will PGNX Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)